PET Imaging Study on Occupancy of Dopamine D2 Receptors and Genotypes After Bupropion Administration

[11C] Raclopride PET Imaging Study That Investigates Relation Between Occupancy of Dopamine D2 Receptors and Genotypes of DRD2 After Bupropion Administration

Bupropion has different effects on D2 dopamine receptors according to genotype.

Open, one arm, single sequence, 2-period, study stratified into 2 DRD2 genotype groups For subjects who volunteer to cease smoking, genotypes are investigated. Twelve subjects are enrolled (6 - DRD2 Taq1A1 allele, 6 - DRD2 Taq1A2 homozygotes). Subjects receive baseline raclopride PET (High Specific Activity, Low Specific Activity).

• Period 1 Subjects receive 150 mg of bupropion SR every day. After 1 week of medication, pharmacokinetic and PET studies are performed.
• Period 2 Subjects receive 150 mg of bupropion SR twice a day. After 1 week of medication, pharmacokinetic and PET studies are performed.

Inclusion Criteria:

• Active smoker (more than 10 cigarettes per day for the past 2 years)

Exclusion Criteria:

• Medical or psychiatric co-morbidity
• Hypersensitive to bupropion